NCT01341548View on ClinicalTrials.gov

Civamide Nasal Solution for Cluster Headache

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2026

Conditions

Episodic Cluster Headache

Interventions

DRUG

Civamide nasal solution 0.01%

20ug/dose, BID for 7 days 0.1 ml to each nostril

All Listed Sponsors

lead

Winston Laboratories

INDUSTRY